SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021)

被引：4

作者：

Martinez-Garcia, Maria ^{[1
,2
]}

Servitja Tormo, Sonia ^{[1
]}

Vilarino Quintela, Noelia ^{[3
]}

Arance Fernandez, Ana ^{[4
]}

Berrocal Jaime, Alfonso ^{[5
]}

Cantos Sanchez de Ibarguen, Blanca ^{[6
]}

Del Barco Berron, Sonia ^{[7
]}

Garcia Campelo, Rosario ^{[8
]}

Girones Sarrio, Regina ^{[9
]}

Manuel Sepulveda-Sanchez, Juan ^{[10
]}

机构：

[1] Hosp Mar, Dept Med Oncol, Barcelona, Spain

[2] CIOCC HM Delfos, Barcelona, Spain

[3] Inst Catala Oncol L Hosp, Dept Med Oncol, Barcelona, Spain

[4] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain

[5] Consorcio Hosp Gen Univ Valencia, Dept Med Oncol, Valencia, Spain

[6] Hosp Univ Puerta Hierro Majadahonda, Dept Med Oncol, Madrid, Spain

[7] Hosp Univ Dr Josep Trueta, Dept Med Oncol, ICO, Girona, Spain

[8] Complexo Hosp Univ A Coruna CHUAC, Dept Med Oncol, La Coruna, Spain

[9] Hosp Univ & Politecn La Fe, Dept Med Oncol, Valencia, Spain

[10] Hosp Univ, Dept Med Oncol, Madrid, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2022年 / 24卷 / 04期

关键词：

Brain metastasis; Blood-brain barrier; Targeted therapies; Immunotherapy; Guidelines; CELL LUNG-CANCER; NEGATIVE BREAST-CANCER; OPEN-LABEL; MUTANT MELANOMA; FOLLOW-UP; CRIZOTINIB; CHEMOTHERAPY; MULTICENTER; SURVIVAL; DABRAFENIB;

D O I：

10.1007/s12094-022-02803-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Central nervous system (CNS) dissemination is a severe complication in cancer and a leading cause of cancer-related mortality. Brain metastases (BMs) are the most common types of malignant intracranial tumors and are reported in approximately 25% of patients with metastatic cancers. The recent increase in incidence of BMs is due to several factors including better diagnostic assessments and the development of improved systemic therapies that have lower activity on the CNS. However, newer systemic therapies are being developed that can cross the blood-brain barrier giving us additional tools to treat BMs. The guidelines presented here focus on the efficacy of new targeted systemic therapies and immunotherapies on CNS BMs from breast, melanoma, and lung cancers.

引用

页码：703 / 711

页数：9

共 50 条

[41] Dynamics of eligibility criteria for central nervous system metastases in non-small cell lung cancer randomized clinical trials over time: A systematic review
Schoenmaekers, Janna Josephus Anna Oda
Dursun, Safiye
Biesmans, Charlotte
Ruysscher, Dirk Karel Maria De
Broen, Martinus Petrus Gertrudis
Remon, Jordi
Dingemans, Anne-Marie Clasina
Hendriks, Lizza Elisabeth Lucia
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 166
[42] The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
Patil, Tejas
Smith, Derek E.
Bunn, Paul A.
Aisner, Dara L.
Le, Anh T.
Hancock, Mark
Purcell, William T.
Bowles, Daniel W.
Camidge, D. Ross
Doebele, Robert C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) : 1717 - 1726
[43] Clinical management and survival of patients with central nervous system hemangiopericytoma in the National Cancer Database
Trifiletti, Daniel M.
Mehta, Gautam U.
Grover, Surbhi
Sheehan, Jason P.
JOURNAL OF CLINICAL NEUROSCIENCE, 2017, 44 : 169 - 174
[44] The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline
Minesh P. Mehta
Nina A. Paleologos
Tom Mikkelsen
Paula D. Robinson
Mario Ammirati
David W. Andrews
Anthony L. Asher
Stuart H. Burri
Charles S. Cobbs
Laurie E. Gaspar
Douglas Kondziolka
Mark E. Linskey
Jay S. Loeffler
Michael McDermott
Jeffrey J. Olson
Roy A. Patchell
Timothy C. Ryken
Steven N. Kalkanis
Journal of Neuro-Oncology, 2010, 96 : 71 - 83
[45] The role of retreatment in the management of recurrent/progressive brain metastases: a systematic review and evidence-based clinical practice guideline
Mario Ammirati
Charles S. Cobbs
Mark E. Linskey
Nina A. Paleologos
Timothy C. Ryken
Stuart H. Burri
Anthony L. Asher
Jay S. Loeffler
Paula D. Robinson
David W. Andrews
Laurie E. Gaspar
Douglas Kondziolka
Michael McDermott
Minesh P. Mehta
Tom Mikkelsen
Jeffrey J. Olson
Roy A. Patchell
Steven N. Kalkanis
Journal of Neuro-Oncology, 2010, 96 : 85 - 96
[46] Morphine facilitates doxorubicin penetration in the central nervous system: a new prospect for therapy of brain tumors
Sardi, Iacopo
JOURNAL OF NEURO-ONCOLOGY, 2011, 104 (02) : 619 - 620
[47] Radiomic-Based MRI for Classification of Solitary Brain Metastases Subtypes From Primary Lymphoma of the Central Nervous System
Zhao, Lin-mei
Hu, Rong
Xie, Fang-Fang
Clay Kargilis, Daniel
Imami, Maliha
Yang, Shuai
Guo, Jiu-Qing
Jiao, Xiao
Chen, Rui-ting
Wei-Hua, Liao
Li, Lang
JOURNAL OF MAGNETIC RESONANCE IMAGING, 2023, 57 (01) : 227 - 235
[48] Molecular neuropathology: an essential and evolving toolbox for the diagnosis and clinical management of central nervous system tumors
Bertero, Luca
Mangherini, Luca
Ricci, Alessia Andrea
Cassoni, Paola
Sahm, Felix
VIRCHOWS ARCHIV, 2024, 484 (02) : 181 - 194
[49] Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy
Fernandez, Mercedes
Nigro, Manuela
Travagli, Alessia
Pasquini, Silvia
Vincenzi, Fabrizio
Varani, Katia
Borea, Pier Andrea
Merighi, Stefania
Gessi, Stefania
PHARMACEUTICS, 2023, 15 (10)
[50] Systemic Therapy for HER2-Positive Central Nervous System Disease: Where We Are and Where Do We Go From Here?
Teplinsky, Eleonora
Esteva, Francisco J.
CURRENT ONCOLOGY REPORTS, 2015, 17 (10)

← 1 2 3 4 5 →